Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Investor Presentation (October 2023)
46 slides from Day One Biopharmaceuticals's investor presentation, Oct 30, 2023
Slide 1: Day One Biopharmaceuticals: Targeted Therapies for People of All Ages
Exhibit 99.2 Day One Biopharmaceuticals Targeted Therapies for People of All Ages October 2023
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some
Slide 3: Cancer Drug Development For People Of All Ages
Cancer Drug Development For People Of All Ages A Mission That Creates Value • Develop medicines for genomically-defined cancers • Establish first-in-class position through rapid registration pathways • Expand to adolescent and adult populations in parallel and pursue those opportunities with the sam
Slide 4: Our Pipeline
Our Pipeline Recent & Anticipated Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Milestones Topline data presented: September 2023 Tovorafenib (DAY101) FDA acceptance of NDA: 1 Relapsed pLGG FIREFLY-1 (pivotal) October 2023 Type II RAF Inhibitor PDUFA target action date: April 30,
Slide 5: Tovorafenib (DAY101) Type II RAF Inhibitor
Tovorafenib (DAY101) Type II RAF Inhibitor
Slide 6: Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children
Pediatric Low-Grade Glioma (pLGG): The Most Common Type Of Brain Tumor In Children PLGGs are chronic and relentless, with patients suffering profound tumor and 6 treatment-associated morbidity that can impact their life trajectory over the long term 7 A Serious and Life-Threatening Disease Disease S
Slide 7: Conventional Treatments Can Be Disruptive To Childhood
Conventional Treatments Can Be Disruptive To Childhood and Can Have Significant Long-Term Consequences Chemotherapy Radiation Surgery • Significant recovery times • Requirement for indwelling • Risk of secondary malignancy catheter and weekly • Risks of complications • Risk of malignant infusions tr
Slide 8: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations
Tovorafenib (DAY101) Inhibits Both BRAF Fusions And BRAF V600 Mutations • Tovorafenib (DAY101) is an investigational, MAPK pathway RAS-independent activation of the MAPK pathway oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both RAS monomeric and dimeric RAF kina
Slide 9: The Current pLGG Treatment Paradigm
The Current pLGG Treatment Paradigm Reflects The Unrelenting Nature Of This Chronic Brain Tumor 1L 2L 3L Presentation Surgical Intervention ~35% ~20% Targeted Tx Targeted Tx Targeted Tx GTR No Recurrence (5-10%) (40-50%) (40-50%) 1 Biopsy (>95%) Suspected ~65% ~50% ~50% pLGG ≤ Partial Eventual Addit
Slide 10: Pivotal Phase Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)
Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) In Relapsed Or Progressive pLGG (FIREFLY-1) – Fully Enrolled & Data Submitted to FDA Trial Design Endpoints (Pivotal Arm 1) 1 • Three arm, open-label, global registrational phase 2 trial • Primary endpoint: ORR based on RANO-HGG , assessed by
Slide 11: Topline Data from Pivotal Phase FIREFLY-1 Trial
Topline Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff
Slide 12: FIREFLY-1 Baseline Patient Characteristics
FIREFLY-1 Baseline Patient Characteristics Location (n=77) Deep midline structures Characteristic Arm 1 (n=77) 12% Optic pathway 51% Median age, years (range) 8 (2-21) Other Sex, n (%) * 16% Male 40 (52) Cerebral hemisphere Female 37 (48) 8% Cerebellum Race, n (%) 6% Brain stem Black or African Amer
Slide 13: Topline Data From FIREFLY-1 Trial – June 2023 Cutoff
Topline Data From Ongoing, Fully Enrolled And NDA Submitted Pivotal Phase 2 FIREFLY-1 Trial – June 5, 2023 Data Cutoff RANO-HGG RAPNO-LGG RANO-LGG (n=69)* (n=76)* (N=76)* ORR, n (%) 46 (67%) 39 (51%) 40 (53%) CBR, n (%) 64 (93%) 62 (82%) 63 (83%) Best Overall Response, n (%) Complete Response (CR) 1
Slide 14: Tovorafenib Safety Data (n=137)
Tovorafenib (DAY101) Safety Data (n=137) • Safety data, based on the 137 patients treated in both Arm 1 and Arm 2 of FIREFLY-1, indicated monotherapy tovorafenib to be generally well-tolerated • The vast majority of adverse events were Grade 1 or Grade 2, with most common treatment-related side effe
Slide 15: Data from Pivotal Phase FIREFLY-1 Trial December 2022 cutoff
Data from Pivotal Phase 2 FIREFLY-1 Trial December 22, 2022 data cutoff
Slide 16: Tumor Response For Patients With RANO-HGG Evaluable Lesions
Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-HGG Evaluable Lesions (n=69) – December 22, 2022 Data Cutoff 1 RANO-HGG Response (IRC) Evaluable n=69 ORR (cCR + cPR + uPR), n (%) 46 (67%)* Clinical benefit rate, n (%) cCR, cPR/uPR, or SD 64 (93%) cCR, cPR/uPR, or SD for 12 mo+ 49 (
Slide 17: Tumor Response For Patients With RAPNO-LGG Evaluable Lesions
Tumor Response To Tovorafenib (DAY101) For All Patients With RAPNO-LGG Evaluable Lesions (n=69*) – December 22, 2022 Data Cutoff 1 RAPNO-LGG Response (IRC) Evaluable n=69 ORR (cCR + cPR/uPR + cMR/uMR), n (%) 35 (51%) Clinical benefit rate, n (%) cCR, cPR/uPR, cMR/uMR, or SD 60 (87%) cCR, cPR/uPR, cM
Slide 18: Tumor Response For Patients With RANO-LGG Evaluable Lesions
Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-LGG Evaluable Lesions (n=76) – December 22, 2022 Data Cutoff 1 RANO-LGG Response (IRC) Evaluable n=76 ORR (cCR + cPR/uPR + cMR/uMR), n (%) 37 (49%) Clinical benefit rate, n (%) cCR, cPR/uPR, cMR/uMR, or SD 63 (83%) cCR, cPR/uPR, cMR/u
Slide 19: Duration Of Tovorafenib Therapy RANO-HGG & RANO-LGG
Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG & RANO-LGG Evaluable Lesions – December 22, 2022 Data Cutoff RANO-HGG (n=69) RANO-LGG (n=76) As of the data cutoff, As of the data cutoff, the median IRC- the median IRC- assessed DOR based on assessed DOR based on RANO-HGG crit
Slide 20: Estimated BRAF-Altered pLGG Patient Population In The U.S.
Estimated BRAF-Altered pLGG Patient Population In The U.S. Estimated BRAF-Altered Patients in the U.S. • An estimated 26,000 children/young adults are living with BRAF-altered (BRAF fusions or BRAF 1-5 V600E mutations) pLGGs in the U.S. today • Despite significant disease burden, many pLGGs undergo
Slide 21: Key Takeaways From FIREFLY-1 Data And Next Steps
Key Takeaways From FIREFLY-1 Data And Next Steps • Clinically meaningful data from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusions or BRAF V600E mutations (“BRAF-altered”) • 67% ORR by RANO-HGG (primary endpoint) • 51% ORR by RAPNO-LGG (secondary endpoint) N
Slide 22: FIREFLY-2/LOGGIC Pivotal Phase Trial in Frontline pLGG
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Frontline pLGG
Slide 23: FIREFLY-2/LOGGIC Pivotal Phase Trial In Frontline pLGG
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Frontline pLGG Trial Design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RANO-LGG criteria, assessed by blinded 1 (DAY101) vs SoC chemotherapy independent cen
Slide 24: FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib
FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib (DAY101) as a Monotherapy and as a Combination with Pimasertib
Slide 25: Phase 1 Study Of Monotherapy Tovorafenib In Solid Tumors (FIRELIGHT-1)
Phase 2 Study Of Monotherapy Tovorafenib (DAY101) In Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints • Single arm, open-label, global phase 1b/2a trial • Primary endpoint: ORR by RECIST version 1.1 for non-CNS solid tumors and RANO-HGG criteria for any CNS tumors • n = 40 patients (approximately
Slide 26: Activity of Tovorafenib In SNX8:BRAF Fusion Spindle Cell Sarcoma
Activity of Tovorafenib (DAY101) In SNX8:BRAF Fusion Spindle Cell Sarcoma A male child spindle cell sarcoma, 5-years of age at diagnosis Months -30 -24 -18 -12 -6 0 6 CR PD CR Diagnosis Targeted Therapy BRAF fusion (FISH) Ifosfamide, doxorubicin, Tovorafenib Tovorafenib Subtotal resection dexrazoxan
Slide 27: FIRELIGHT-1 Phase 1b/2 Trial Tovorafenib Combination with Pimasertib
FIRELIGHT-1 Phase 1b/2 Trial Evaluating Tovorafenib (DAY101) as a Combination with Pimasertib
Slide 28: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor
Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors • Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 • Extensive non-clinical and clinical develo
Slide 29: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib
Vertical MAPK Pathway Inhibition With Tovorafenib (DAY101) And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors BRAF KRAS or NRAS non-V600 mutant mutant MEK RAF/ PI3K/m RAL MEK/ERK TOR ERK Proliferation, survival Proliferation, survival Type II RAFi + MEKI Type II RAFi + MEKi Type II R
Slide 30: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)
Tovorafenib (DAY101) / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints 2 • Combination dose escalation, global phase 1b/2 trial • Phase 1b: PK, PD and Safety, MTD/RP2D • Phase 1b, BOIN (adaptive), n = 10/cohort (approximately) • Phase 2: Efficacy (ORR, DOR) • Phase 2, S
Slide 31: Summary
NZ Day One BIOPHARMACEUTICALS Summary
Slide 32: Financial Summary: DAWN
Financial Summary: DAWN Cash, cash equivalents and short-term investments ~87.0 million shares of common stock as of June 30, 2023: $442.9 million (no debt) outstanding as of August 1, 2023 Six Months Ended Six Months Ended $ Millions 6/30/23 6/30/22 R&D Expense $60.0 $37.6 G&A Expense $35.1 $26.9 N
Slide 33: Next Steps
Next Steps FIREFLY-1 • Initiated rolling NDA in May 2023 • New topline data presented in September 2023 • FDA acceptance of NDA and priority review granted in October 2023 • PDUFA target action date of April 30, 2024 FIREFLY-2 • Advance tovorafenib as a frontline therapy for patients with pLGG • Cur
Slide 34: Appendix
Appendix `
Slide 35: Duration Of Tovorafenib Therapy For Patients With RANO-HGG Evaluable Lesions
Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions (n=69) 2.8 Median time to response* MONTHS 11/17 patients with stable disease <12 months remain on treatment as of data cutoff Median duration of 10.8 MONTHS treatment* Ongoing treatment Partial response Discon
Slide 36: RANO-LGG Unconfirmed PR Patients Continue On Treatment With Deepening Of Response
All RANO-LGG Unconfirmed PR Patients Continue On Treatment With Demonstrable Deepening Of Response (n=8) Responses for Patients with Unconfirmed Partial Response by RANO-LGG SD MR PR CR Months from Baseline All 8 patients with unconfirmed partial response by RANO-LGG remain on treatment as of May 23
Slide 37: Nearly Half Of Patients With Best Response Of PD By RANO-LGG Have Tumor Stabilization
Nearly Half Of Patients With Best Response Of PD By RANO-LGG Have Tumor Stabilization And Response With Continued Treatment (n=11) Ongoing treatment Discontinued treatment 5/11 patients with best response of PD by RANO-LGG remain on treatment as of May 23, 2023 37 Individual patient response data is
Slide 38: Tovorafenib Safety Data (n=136)
Tovorafenib (DAY101) Safety Data (n=136) • The vast majority of treatment-emergent AEs Treatment-emergent AEs Treatment-related AEs were Grade 1 or 2 Preferred term, n (%) Any grade Grade ≥3 Any grade Grade ≥3 • 39 patients (29%) required dose modifications Any AE 136 (100) 68 (50) 133 (98) 47 (35)
Slide 39: Case Study: KIAA1549-BRAF Fusion Optic Pathway Glioma
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis -36 6 Months -30 -24 -18 -12 -6 0 PR Diagnostic biopsy 3L: Tovorafen
Slide 40: Case Study: KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation Months -84 -72 -60 -48 -36 -24 -12 0 12 PR Suboccipital 2L: Carboplatin/vincristine cra
Slide 41: Case Study: BRAF V600E Mutation Deep Midline Astrocytoma
Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty Months -60 -48 -36 -24 -12 0 12 PR Subtotal 1L: Carboplatin/vincristine 2L: Dabrafenib 3L: Tovorafenib resect
Slide 42: Case Study: KIAA1549-BRAF Fusion Optic Pathway Glioma
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma 8-year-old boy with relapsed pilomyxoid astrocytoma of the optic pathway, with visual loss in right eye, visual field loss in left eye, fatigue, intermittent nausea/vomiting, intermittent headaches, anorexia, a
Slide 43: FIREFLY-2/LOGGIC: Pivotal Phase Study In Newly Diagnosed pLGG
FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG • Collaboration between Day One and the Approximately 100 potential sites (~65 from the LOGGIC consortium) LOGGIC consortium, internationally recognized experts in pLGG research ‒ Coupled with the LOGGIC-CORE mol
Slide 44: Results From Independent Radiology Review Of PNOC014
Results From Independent Radiology Review Of PNOC014 Best response from baseline RANO-HGG: Response assessment for neuro- oncology-high grade glioma Volumetric image analysis (exploratory) RAPNO: Response assessment for pediatric neuro-oncology (exploratory) 44 Date of data cutoff: 02 JAN 2020. Wrig
Slide 45: Multiple Rapid, Deep And Durable Responses In PNOC014
Multiple Rapid, Deep And Durable Responses Observed Following Initiation Of Tovorafenib (DAY101) Treatment Of pLGG Patients In PNOC014 Growth kinetics of Target Lesions from Screening 45 Date of data cutoff: 02 JAN 2020. Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020. Fangusaro
Slide 46: Drug-related Adverse Events Observed for Tovorafenib in PNOC014
Drug-related Adverse Events Observed for Tovorafenib (DAY101) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Drug-related AEs for Tovorafenib (DAY101) Drug-related AEs for selumetinib Toxicities Grade 1-2 Grade 3 Grade 4 Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Increa
Day One Biopharmaceuticals — Investor Presentation (October 2023) on 6ix